CO2019015086A2 - Moduladores de tetrahidropiridopirazina de gpr6 - Google Patents
Moduladores de tetrahidropiridopirazina de gpr6Info
- Publication number
- CO2019015086A2 CO2019015086A2 CONC2019/0015086A CO2019015086A CO2019015086A2 CO 2019015086 A2 CO2019015086 A2 CO 2019015086A2 CO 2019015086 A CO2019015086 A CO 2019015086A CO 2019015086 A2 CO2019015086 A2 CO 2019015086A2
- Authority
- CO
- Colombia
- Prior art keywords
- gpr6
- tetrahydropyridopyrazine
- modulators
- compound
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe un compuesto de fórmula 1 como se describe en la memoria descriptiva y una sal farmacéuticamente aceptable de este. La presente descripción también se refiere a materiales y métodos para preparar el compuesto de fórmula 1, a composiciones farmacéuticas que lo contienen y a su uso para tratar enfermedades, trastornos y afecciones asociadas con GPR6.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762520430P | 2017-06-15 | 2017-06-15 | |
US201762591247P | 2017-11-28 | 2017-11-28 | |
US201862649856P | 2018-03-29 | 2018-03-29 | |
US201862672261P | 2018-05-16 | 2018-05-16 | |
PCT/US2018/037687 WO2018232202A1 (en) | 2017-06-15 | 2018-06-15 | Tetrahydropyridopyrazine modulators of gpr6 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019015086A2 true CO2019015086A2 (es) | 2020-04-13 |
Family
ID=64656005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0015086A CO2019015086A2 (es) | 2017-06-15 | 2019-12-30 | Moduladores de tetrahidropiridopirazina de gpr6 |
Country Status (19)
Country | Link |
---|---|
US (1) | US10406157B2 (es) |
EP (1) | EP3638673B1 (es) |
JP (2) | JP7460369B2 (es) |
KR (1) | KR20200014796A (es) |
CN (1) | CN110730781B (es) |
AU (1) | AU2018285677B2 (es) |
BR (1) | BR112019026430A2 (es) |
CA (1) | CA3067032A1 (es) |
CO (1) | CO2019015086A2 (es) |
DK (1) | DK3638673T3 (es) |
FI (1) | FI3638673T3 (es) |
IL (1) | IL271332B2 (es) |
JO (1) | JOP20180057A1 (es) |
LT (1) | LT3638673T (es) |
MX (1) | MX2019014940A (es) |
PH (1) | PH12019502792A1 (es) |
SG (1) | SG11201912149WA (es) |
TW (1) | TWI775874B (es) |
WO (1) | WO2018232202A1 (es) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US7229557B2 (en) * | 2004-02-04 | 2007-06-12 | Konec, Inc. | Method to separate stereoisomers |
WO2011005636A1 (en) * | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Tetrahydronapthyridine orexin receptor antagonists |
JO3466B1 (ar) * | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
WO2015123505A1 (en) | 2014-02-14 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Pyridopyrazines modulators of gpr6 |
WO2015123533A1 (en) * | 2014-02-14 | 2015-08-20 | Takeda Pharmaceutical Company Limited | Pyrazines modulators of gpr6 |
-
2017
- 2017-06-15 JO JOP/2018/0057A patent/JOP20180057A1/ar unknown
-
2018
- 2018-06-15 FI FIEP18818829.6T patent/FI3638673T3/fi active
- 2018-06-15 DK DK18818829.6T patent/DK3638673T3/da active
- 2018-06-15 WO PCT/US2018/037687 patent/WO2018232202A1/en unknown
- 2018-06-15 TW TW107120685A patent/TWI775874B/zh active
- 2018-06-15 CA CA3067032A patent/CA3067032A1/en active Pending
- 2018-06-15 US US16/009,308 patent/US10406157B2/en active Active
- 2018-06-15 JP JP2019563277A patent/JP7460369B2/ja active Active
- 2018-06-15 SG SG11201912149WA patent/SG11201912149WA/en unknown
- 2018-06-15 EP EP18818829.6A patent/EP3638673B1/en active Active
- 2018-06-15 AU AU2018285677A patent/AU2018285677B2/en active Active
- 2018-06-15 MX MX2019014940A patent/MX2019014940A/es unknown
- 2018-06-15 LT LTEPPCT/US2018/037687T patent/LT3638673T/lt unknown
- 2018-06-15 BR BR112019026430-2A patent/BR112019026430A2/pt unknown
- 2018-06-15 CN CN201880038831.4A patent/CN110730781B/zh active Active
- 2018-06-15 KR KR1020197037207A patent/KR20200014796A/ko not_active Application Discontinuation
-
2019
- 2019-12-10 PH PH12019502792A patent/PH12019502792A1/en unknown
- 2019-12-11 IL IL271332A patent/IL271332B2/en unknown
- 2019-12-30 CO CONC2019/0015086A patent/CO2019015086A2/es unknown
-
2022
- 2022-10-05 JP JP2022160819A patent/JP7497400B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
LT3638673T (lt) | 2024-09-10 |
BR112019026430A2 (pt) | 2020-07-14 |
AU2018285677B2 (en) | 2022-07-14 |
KR20200014796A (ko) | 2020-02-11 |
US20180360831A1 (en) | 2018-12-20 |
JP2022188199A (ja) | 2022-12-20 |
IL271332A (en) | 2020-01-30 |
CN110730781B (zh) | 2023-05-05 |
JP7460369B2 (ja) | 2024-04-02 |
DK3638673T3 (da) | 2024-09-16 |
PH12019502792A1 (en) | 2020-09-14 |
IL271332B (en) | 2022-10-01 |
EP3638673A1 (en) | 2020-04-22 |
WO2018232202A1 (en) | 2018-12-20 |
JP2020523287A (ja) | 2020-08-06 |
EP3638673A4 (en) | 2021-03-24 |
EP3638673B1 (en) | 2024-07-17 |
US10406157B2 (en) | 2019-09-10 |
RU2019144408A (ru) | 2021-07-15 |
JP7497400B2 (ja) | 2024-06-10 |
IL271332B2 (en) | 2023-02-01 |
TW201906844A (zh) | 2019-02-16 |
RU2019144408A3 (es) | 2021-09-07 |
AU2018285677A1 (en) | 2019-12-19 |
CN110730781A (zh) | 2020-01-24 |
JOP20180057A1 (ar) | 2019-01-30 |
FI3638673T3 (fi) | 2024-09-13 |
SG11201912149WA (en) | 2020-01-30 |
TWI775874B (zh) | 2022-09-01 |
MX2019014940A (es) | 2020-02-19 |
CA3067032A1 (en) | 2018-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
UY37617A (es) | Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo | |
CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
UY36112A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
BR112015031903A8 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto | |
AR094553A1 (es) | Formas de oxadiazolpirazina | |
DOP2018000115A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
CR20150056A (es) | Derivados de azaindol | |
CO2019007830A2 (es) | Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas | |
DOP2017000034A (es) | Compuestos de imidazopiridazina | |
CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
CO2018012002A2 (es) | Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor | |
CO2018005983A2 (es) | Compuestos de isoindol | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
CR20160558A (es) | Compuesto de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer | |
NI201900094A (es) | COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
ECSP16096831A (es) | Derivados de naftiridinadiona | |
CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
CL2017001588A1 (es) | Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos | |
AR107937A1 (es) | Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer | |
CL2021000282A1 (es) | Inhibidores de ckd8/19 | |
UY37622A (es) | Derivados de pirazol como inhibidores de bromodominio de la familia bet y su uso en aplicaciones terapéuticas | |
ECSP17045054A (es) | Derivados de fumagilol |